Emerging Allergy Treatments Pipeline 2026

Instead of years of weekly or monthly allergy shots, intralymphatic immunotherapy delivers a small number of injections — often as few as three — directly into a lymph node under ultrasound guidance, where the immune system processes allergens more efficiently. Most published studies to date are early-stage (Phase I/II) trials in grass, tree, and bee-venom allergy, though at least one larger placebo-controlled trial has since been completed. Confirmatory late-stage trials and long-term follow-up are still needed before it becomes broadly available.

Peptide immunotherapy uses short synthetic fragments of allergen proteins — rather than whole allergen extracts — aiming to retrain T-cell tolerance with fewer systemic reactions and a shorter course than conventional immunotherapy. A high-profile Phase III trial of a cat-allergen peptide vaccine (Circassia's Cat-SPIRE) failed to outperform placebo in 2016, and related grass and ragweed peptide programs were discontinued as a result. Newer peptide approaches, including ones targeting cat allergens beyond Fel d 1, remain in earlier-stage research and have not yet reached late-stage trials.

Omalizumab, an anti-IgE antibody already FDA-approved for moderate-to-severe asthma and chronic hives, is under study as a standalone or add-on treatment for allergic rhinitis in people who don't respond well to standard antihistamines or nasal steroids. Newer biologics targeting other allergic-inflammation pathways are in earlier trials for the same population.

Under-the-tongue immunotherapy tablets are already FDA-approved for grass, ragweed, and dust mite allergy. Manufacturers are now studying and developing SLIT tablets for additional common allergens, aiming to bring the same at-home, needle-free format to a wider range of triggers.

Most antihistamines on the market block the H1 receptor. Researchers are now investigating compounds that target the H3 and H4 histamine receptors, which play a role in inflammatory and itch pathways not well addressed by existing allergy medications. This work is still preclinical or in the earliest stages of human study.